Leerink Partnrs Has Pessimistic Outlook of ELAN Q4 Earnings

Elanco Animal Health Incorporated (NYSE:ELAN) – Equities researchers at Leerink Partnrs lowered their Q4 2025 EPS estimates for Elanco Animal Health in a research note issued to investors on Wednesday, November 5th. Leerink Partnrs analyst D. Clark now forecasts that the company will post earnings per share of $0.11 for the quarter, down from their previous estimate of $0.14. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Elanco Animal Health’s current full-year earnings is $0.91 per share. Leerink Partnrs also issued estimates for Elanco Animal Health’s FY2026 earnings at $0.98 EPS and FY2027 earnings at $1.15 EPS.

A number of other research analysts have also recently issued reports on ELAN. Leerink Partners upgraded Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 target price on the stock in a research report on Thursday, July 17th. Wall Street Zen downgraded Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. Zacks Research raised Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 3rd. Piper Sandler lifted their target price on shares of Elanco Animal Health from $12.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, August 11th. Finally, Stifel Nicolaus upped their price target on shares of Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Elanco Animal Health presently has an average rating of “Moderate Buy” and a consensus price target of $20.29.

Elanco Animal Health Price Performance

Shares of ELAN traded down $0.33 during trading hours on Friday, hitting $21.19. 494,185 shares of the company were exchanged, compared to its average volume of 5,904,285. The company has a quick ratio of 1.40, a current ratio of 2.60 and a debt-to-equity ratio of 0.61. Elanco Animal Health has a fifty-two week low of $8.02 and a fifty-two week high of $22.98. The company has a market cap of $10.53 billion, a price-to-earnings ratio of 351.56, a P/E/G ratio of 3.30 and a beta of 1.71. The firm’s fifty day moving average is $20.11 and its 200 day moving average is $16.07.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.06. Elanco Animal Health had a return on equity of 7.51% and a net margin of 0.78%.The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter in the prior year, the business posted $0.13 earnings per share. The firm’s quarterly revenue was up 10.4% compared to the same quarter last year. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS. Q4 2025 guidance at 0.090-0.120 EPS.

Institutional Investors Weigh In On Elanco Animal Health

Several institutional investors and hedge funds have recently made changes to their positions in ELAN. AlphaQuest LLC lifted its position in shares of Elanco Animal Health by 13.7% during the 3rd quarter. AlphaQuest LLC now owns 5,953 shares of the company’s stock valued at $120,000 after acquiring an additional 718 shares during the period. Jones Financial Companies Lllp raised its holdings in shares of Elanco Animal Health by 15.2% during the third quarter. Jones Financial Companies Lllp now owns 6,065 shares of the company’s stock valued at $119,000 after purchasing an additional 798 shares during the period. MTM Investment Management LLC boosted its position in shares of Elanco Animal Health by 5.5% during the 2nd quarter. MTM Investment Management LLC now owns 15,268 shares of the company’s stock worth $218,000 after purchasing an additional 800 shares in the last quarter. HighTower Advisors LLC grew its stake in shares of Elanco Animal Health by 7.0% in the 1st quarter. HighTower Advisors LLC now owns 12,445 shares of the company’s stock valued at $131,000 after buying an additional 810 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. increased its position in Elanco Animal Health by 80.3% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after buying an additional 900 shares in the last quarter. Institutional investors own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.